drugset / Trial / NCT06840769
A Clinical Trial to Assess Safety and Pharmacokinetics of Fosnetupitant 235 mg and Metabolites in Healthy Volunteers
Non-randomizedSequentialOpen-labelHealth-services research
Summary
This clinical trial will include two parts, i.e., Part A and Part B. The goal of the Part A is to define the shortest safe and tolerable duration of an intravenous injection of Fosnetupitant 235 mg solution among 4 durations tested in male and female adult healthy volunteers. In study part A, researchers will compare Fosnetupitant 235 mg solution to Akynzeo® solution. The duration determined in Part A will be investigated in study Part B. The Part B of the study was not performed.
Timeline
- Start
- 2023-06-17
- Primary completion
- 2023-10-18
- Completion
- 2023-10-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Palonosetron | Other / unclassified | 0.25 mg | Intravenous |
| Subject | fosnetupitant | Small molecule | 235 mg | Intravenous |
Indications
No indication recorded.